Editas Medicine (EDIT) Projected to Announce Quarterly Earnings on Tuesday

Editas Medicine (NASDAQ:EDIT) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Editas Medicine to announce earnings of ($0.30) per share and revenue of $2.8460 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Editas Medicine had a negative net margin of 281.59% and a negative return on equity of 677.39%. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $6.37 million. On average, analysts expect Editas Medicine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Editas Medicine Stock Performance

Editas Medicine stock traded up $0.10 during trading on Tuesday, reaching $2.75. 619,056 shares of the company’s stock were exchanged, compared to its average volume of 2,023,839. Editas Medicine has a 52-week low of $1.66 and a 52-week high of $4.54. The firm has a market cap of $268.76 million, a price-to-earnings ratio of -2.23 and a beta of 2.14. The company’s 50-day moving average is $2.94 and its two-hundred day moving average is $2.62.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Chardan Capital boosted their price objective on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. Finally, Wall Street Zen cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Sunday, May 10th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Editas Medicine currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.40.

Insider Activity

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the sale, the chief executive officer owned 248,313 shares in the company, valued at approximately $670,445.10. This represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 21,503 shares of company stock valued at $57,910. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Editas Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of EDIT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock worth $3,016,000 after buying an additional 1,430,000 shares during the last quarter. Acadian Asset Management LLC increased its position in Editas Medicine by 288.5% in the first quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock worth $869,000 after buying an additional 558,567 shares during the period. Geode Capital Management LLC lifted its stake in Editas Medicine by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,964,298 shares of the company’s stock valued at $4,323,000 after buying an additional 20,521 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Editas Medicine by 15.2% in the second quarter. JPMorgan Chase & Co. now owns 1,065,722 shares of the company’s stock valued at $2,345,000 after buying an additional 140,916 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Editas Medicine by 500.0% during the second quarter. Bridgeway Capital Management LLC now owns 120,000 shares of the company’s stock valued at $264,000 after acquiring an additional 100,000 shares during the period. 71.90% of the stock is owned by institutional investors.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and ?-thalassemia using an ex vivo editing approach.